Fujirebio Acquires ADx NeuroSciences

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.

BioVie Acquires Biopharma Assets of NeurMedix

June 11, 2021

Pharmaceuticals

BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.

Nihon Kohden Acquires 71.4% Stake in Ad‑Tech from ARCHIMED

November 26, 2024

Medical Devices

Nihon Kohden has acquired a 71.4% stake in NeuroAdvanced Corp., the parent of Ad‑Tech Medical Instrument Corporation, from ARCHIMED’s MED II fund, with ARCHIMED retaining a 28.6% minority stake and entering a joint venture with Nihon Kohden. The deal brings together Nihon Kohden’s EEG and monitoring platform with Ad‑Tech’s intracranial neuroelectrodes to strengthen epilepsy diagnostics and expand Ad‑Tech’s global reach across North America, Europe and Asia.

Clario Acquires NeuroRx

March 19, 2025

Healthcare Services

Clario has acquired NeuroRx, a Montreal-based imaging analysis provider specializing in neuroimaging for clinical trials, to strengthen Clario's neuroscience capabilities. NeuroRx founder Douglas Arnold will join Clario as Senior Scientific Advisor as the company integrates NeuroRx's imaging expertise to support drug development in CNS indications.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.